HEALTH

FDA Panel Rejects U.S. Bioscience Inc.’s Ethyol: The advisory panel unanimously killed the firm’s second attempt to have Ethyol recommended for approval. Ethyol is designed to protect cancer patients from the side effects of chemotherapy. The medical experts assembled by the Food and Drug Administration found that the drug appears to have some biological effect in ovarian cancer patients but not enough to recommend approval. The full FDA generally follows its advisory panels’ recommendations. The European Union’s drug review committee recommended approval for Ethyol in September based on the same clinical trial data presented to the FDA panel. Britain has approved Ethyol.